Last reviewed · How we verify
Anelazol Sodium Enteric-coated Tablets
Anelazol sodium is an anti-inflammatory agent that inhibits leukotriene synthesis and reduces inflammatory mediator production.
Anelazol sodium is an anti-inflammatory agent that inhibits leukotriene synthesis and reduces inflammatory mediator production. Used for Allergic rhinitis, Asthma, Inflammatory bowel conditions.
At a glance
| Generic name | Anelazol Sodium Enteric-coated Tablets |
|---|---|
| Sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
| Drug class | Leukotriene inhibitor / Anti-inflammatory agent |
| Target | Leukotriene synthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammatory diseases |
| Phase | FDA-approved |
Mechanism of action
Anelazol sodium functions as a leukotriene inhibitor, suppressing the production of inflammatory mediators involved in immune and inflammatory responses. The enteric coating allows targeted delivery to the small intestine, minimizing gastric irritation while optimizing absorption. This mechanism makes it suitable for treating inflammatory and allergic conditions.
Approved indications
- Allergic rhinitis
- Asthma
- Inflammatory bowel conditions
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: